Open access · CC-BY
via OpenAlex
A pooled analysis of mesenchymal stem cell-based therapy for liver disease
Lu Zhao, Shanquan Chen, Xiaowei Shi, Hongcui Cao, Lanjuan Li
Stem Cell Research & Therapy · 2018 · ▲ 99 citations
Abstract
BACKGROUND: Liver disease is a major cause of death and disability. Mesenchymal stem cells (MSCs) show promise for the treatment of liver disease. However, whether MSC-based therapy is more effective than conventional treatment is unclear, as are the optimal MSC source, the administration frequency, and the most effective MSC delivery route. We therefore undertook a systematic review and meta-analysis of the therapeutic efficacy of MSCs against liver disease and the related factors. METHODS: We systematically searched Medline (PubMed), Cochrane Library, EMBASE, ClinicalTrials.gov, and SinoMed CBM to identify studies published up to June 2017 involving liver disease patients receiving MSC-based therapy and which reported estimates of liver function during the follow-up period. RESULTS: Thirty-nine studies were selected from 672 publications. According to a meta-analysis of 23 controlled studies, compared with conventional treatment MSC therapy significantly improves liver function in patients with liver disease in terms of the model of end-stage liver disease score, albumin, alanine aminotransferase, and total bilirubin levels, and prothrombin time, up to 6 months after administration. However, it has no beneficial effects in terms of prothrombin activity, international normalized ratio, or cholinesterase level. Considerable heterogeneity was identified at most time points. Subgroup analyses showed that a single MSC injection was more effective than multiple injections, MSC administration was more effective via the hepatic artery than the peripheral vein, and MSCs derived from bone marrow were more effective than those derived from the umbilical cord. CONCLUSIONS: MSC-based therapy is relatively safe and improves liver function during the first 6 months after administration. A single injection administration via the hepatic artery and MSCs derived from bone marrow are optimal in terms of improving liver function. However the significant heterogeneity among studies and discontinuous results of the subgroup meta-analysis should be addressed; moreover the long-term efficacy of MSC therapy warrants further investigation.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1186/s13287-018-0816-2
- Canonical
- link ↗
- Fetched
- 2026-10-10 MST
Cite this
APA
Zhao, L., Chen, S., Shi, X., Cao, H., & Li, L. (2018). A pooled analysis of mesenchymal stem cell-based therapy for liver disease. <em>Stem Cell Research & Therapy</em>. https://doi.org/10.1186/s13287-018-0816-2
Vancouver
Zhao L, Chen S, Shi X, Cao H, Li L. A pooled analysis of mesenchymal stem cell-based therapy for liver disease. Stem Cell Research & Therapy. 2018. doi:10.1186/s13287-018-0816-2.
BibTeX
@article{lu2018Apoole,
title = {A pooled analysis of mesenchymal stem cell-based therapy for liver disease},
author = {Lu Zhao and Shanquan Chen and Xiaowei Shi and Hongcui Cao and Lanjuan Li},
journal = {Stem Cell Research & Therapy},
year = {2018},
doi = {10.1186/s13287-018-0816-2},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Inflammation and Regeneration 2023
Open access · CC-BY
Bone regeneration in inflammation with aging and cell-based immunomodulatory therapy
Molecular Medicine Reports 2018
Open access · CC-BY
Aging, rather than Parkinson's disease, affects the responsiveness of PBMCs to the immunosuppression of bone marrow mesenchymal stem cells
Health Science Reports 2024
Open access · CC-BY
Mesenchymal stem cell therapy in diabetic foot ulcer: An updated comprehensive review
Annals of Translational Medicine 2022
Open access · CC-BY
Mesenchymal stem cells alleviate aging in vitro and in vivo
Circulation 2010
Open access · OA
Differentiation of Allogeneic Mesenchymal Stem Cells Induces Immunogenicity and Limits Their Long-Term Benefits for Myocardial Repair
Circulation 2004
Open access · OA